Drug intelligence / Profile preview

ZEP-3

Development stage: Phase 2
Lead developer: Shulov Innovative Science
Modality: Peptides, Small Molecules
Administration: Topical, Transdermal

Overview

ZEP-3 is a synthetic short peptide drug developed by SIS Shulov Innovative Science for topical use. It is being investigated primarily for the treatment of herpes virus infections (notably herpes labialis) and atopic dermatitis. The drug acts as a virus replication inhibitor and has also demonstrated analgesic activity in indications such as osteoarthritis, herpes labialis, and ocular pain. As of the latest updates, it has reached phase II clinical trials for both atopic dermatitis and herpes labialis[1][2][3]. The route of administration studied includes transdermal ointment application[3].

Other names: ZEP 3ZEP3ZEP-3ZEP-3NaZEP3NaZEP 3Na

Targets

Herpes simplex virus replication machinery

Beyond the preview

Go deeper on ZEP-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZEP-3.

Explore the full profile